“`html
Breakthrough in Stem Cell Research Paves Way for Accessible Immunotherapies
A new study published on January 7 in Cell Stem Cell represents a significant advancement in the field of cell therapy, addressing key challenges in the scalable and affordable production of immune cells for treating diseases like cancer, autoimmune disorders, and infectious diseases. Researchers at the University of British Columbia (UBC) have developed a reliable method for growing both helper and killer T cells from stem cells, potentially enabling the creation of “off-the-shelf” therapies.
The Promise of Engineered Cell Therapies
Engineered cell therapies, such as CAR-T cell therapy, have shown remarkable success in treating certain cancers. These therapies reprogram a patient’s own immune cells to target and destroy diseased cells,effectively functioning as “living drugs” . However, current cell therapies are often expensive, complex to manufacture, and inaccessible to many patients becuase they rely on using a patient’s own cells, requiring a personalized and time-consuming process.
“The long-term goal is to have off-the-shelf cell therapies that are manufactured ahead of time and on a larger scale from a renewable source like stem cells,” explains Dr. Megan Levings,a professor of surgery and biomedical engineering at UBC . “This would make treatments much more cost-effective and readily available when patients need them.”
the Critical Role of Helper and Killer T Cells
Effective cancer cell therapies frequently enough require the coordinated action of two main types of T cells: killer T cells,which directly attack diseased cells,and helper T cells,which orchestrate the immune response.Helper T cells detect threats, activate other immune cells, and sustain the immune response over time. While scientists have previously been able to generate killer T